Alphabet has shed its controlling stake in its life‑sciences arm, which will now operate as a public corporation called Verily Health Inc. The company closed a $300 million funding round, shifting from an LLC to a corporate structure. As a result, Alphabet holds only a minority share in the venture.

Verily’s new focus centers on artificial intelligence, echoing the company’s long‑term ambition to blend clinical rigor with data science. Chairman and CEO Stephen Gillett said the goal is “to deliver the next generation of healthcare—precise and personal.” The shift follows years of projects, from eye‑scan heart‑disease prediction to an opioid‑addiction center.

Earlier this year, Verily shuttered its medical‑device division, a move that signaled a pivot toward AI‑driven solutions. The company’s portfolio has also included eye‑scan diagnostics and a community‑based addiction program, illustrating its willingness to tackle diverse health challenges. The reorganization positions Verily to compete with other AI‑health startups.

With Alphabet now a minority shareholder, Verily Health Inc. can chart an independent course, leveraging its AI expertise to deliver personalized care tools. The move underscores a broader industry trend toward data‑centric health solutions and signals that even established tech giants are willing to spin off niche units to pursue focused innovation.